Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH).
作者信息
Schattenberg Jörn M
机构信息
Metabolic Liver Research Center and Medicine, University Medical Center, Mainz, Germany.
出版信息
Expert Opin Investig Drugs. 2020 Feb;29(2):111-113. doi: 10.1080/13543784.2020.1721150. Epub 2020 Feb 3.
Abstract
摘要
相似文献
1
Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH).约恩·沙滕贝格教授阐述了非酒精性脂肪性肝炎（NASH）的关键治疗和诊断方法。
Expert Opin Investig Drugs. 2020 Feb;29(2):111-113. doi: 10.1080/13543784.2020.1721150. Epub 2020 Feb 3.
2
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）：患病率、治疗创新及临床开发的障碍
Expert Opin Investig Drugs. 2020 Feb;29(2):115-116. doi: 10.1080/13543784.2020.1721167. Epub 2020 Feb 3.
3
Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.新兴疗法治疗非酒精性脂肪性肝炎：系统评价。
Pharmacotherapy. 2021 Mar;41(3):315-328. doi: 10.1002/phar.2489. Epub 2021 Feb 17.
4
Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).Elafibranor：一种有潜力用于治疗非酒精性脂肪性肝炎（NASH）的药物。
Expert Opin Investig Drugs. 2020 Feb;29(2):117-123. doi: 10.1080/13543784.2020.1668375. Epub 2019 Sep 25.
5
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.非酒精性脂肪性肝病患者真实世界观察性队列的设计与原理：TARGET-NASH研究
Contemp Clin Trials. 2017 Oct;61:33-38. doi: 10.1016/j.cct.2017.07.015. Epub 2017 Jul 19.
6
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.利拉鲁肽、奥贝胆酸和 Elafibranor 在经活检证实的非酒精性脂肪性肝炎肥胖小鼠模型中的代谢和肝脏作用。
World J Gastroenterol. 2018 Jan 14;24(2):179-194. doi: 10.3748/wjg.v24.i2.179.
7
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.非酒精性脂肪性肝炎（NASH）——当前的治疗建议及未来发展
Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9.
8
Efficacy and safety of drugs for nonalcoholic steatohepatitis.非酒精性脂肪性肝炎药物的疗效和安全性。
J Dig Dis. 2021 Feb;22(2):72-82. doi: 10.1111/1751-2980.12967.
9
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.非酒精性脂肪性肝炎和非酒精性脂肪性肝病：新兴药物、治疗靶点以及转化与临床挑战
Expert Opin Investig Drugs. 2020 Feb;29(2):87. doi: 10.1080/13543784.2020.1721169. Epub 2020 Jan 29.
10
Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病
Prim Care. 2017 Dec;44(4):599-607. doi: 10.1016/j.pop.2017.07.003.
Zotero 插件